Dear Sir/Dear Madam,

We are reaching out today on behalf of Lundbeck Canada to share an important update on our ongoing drug shortages affecting different formats of SABRIL® (vigabatrin), indicated for the adjunctive management of partial epilepsies and the management of infantile spasms.

While we know you have been made aware of this issue in recent months, we wanted to make sure that we continue to provide our valued stakeholders with up-to-date and accurate information regarding treatment availability.

We are pleased to share with you that the shortage of SABRIL 500 mg tablets has been resolved, with supply being made available at the end of March 2024. With a valid prescription, patients can now get SABRIL tablets from their pharmacy.

Additionally, the shortage of SABRIL 500mg powder for oral solution is targeted to be resolved by approximately mid-May 2024. We have been working diligently to resolve this shortage and appreciate the understanding of the Canadian patient community. For current updates, please visit Drug Shortages Canada’s webpage for the powder for oral solution format of SABRIL.

At Lundbeck, we understand how important it is for patients to have access to the medications they need. For patients and their families, we know there still may be questions and concerns. We encourage all patients affected by a shortage to consult with their healthcare professional, who can make a decision about their treatment plan.

If you have any further questions, please feel free to reach out to us at any time. If your questions are medical in nature, please contact your healthcare professional. For questions about the product itself, please see the Canadian SABRIL monograph for complete product information or contact Lundbeck Canada Medical Information at 1-866-880-4636 or canadamedicalinformation@lundbeck.com.

Regards,

Fakher Aissa
Vice President, Market Access & Public Affairs
Lundbeck Canada

Martine Hubert, MD
Vice President, Medical and Regulatory Affairs
Lundbeck Canada Inc.